Market Cap 12.06M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 364,200
Avg Vol 3,580,728
Day's Range N/A - N/A
Shares Out 10.76M
Stochastic %K 24%
Beta 0.96
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
transition_state
transition_state Nov. 26 at 2:58 PM
0 · Reply
Treechain
Treechain Nov. 26 at 2:50 PM
$PHIO charts are starting to show buy
0 · Reply
Treechain
Treechain Nov. 26 at 2:28 PM
$PHIO phase 1b enrollment
0 · Reply
Erhnadgzl
Erhnadgzl Nov. 26 at 8:32 AM
$PHIO Preparations have begun for a very big deal that will happen soon.
0 · Reply
Erhnadgzl
Erhnadgzl Nov. 26 at 8:30 AM
$PHIO lets gooo 4 dolar guys
0 · Reply
ckruel
ckruel Nov. 25 at 9:33 PM
$PHIO On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial, which evaluates safety and tolerability, showed promising results with several patients achieving complete or partial responses, and no dose-limiting toxicities observed. This milestone advances PH-762 as a potential treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with pathology results expected in Q1 2026. Recent price target $14 usd
0 · Reply
KuruHabesha
KuruHabesha Nov. 25 at 6:03 PM
$PHIO Starter!
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Nov. 25 at 5:04 PM
$PHIO Seems weird to me - Old Bob buys stock and then makes announcement - wonder if his dream team did also or just friends and family - but even the pump was ineffective
0 · Reply
JimCramerisadoofus
JimCramerisadoofus Nov. 25 at 4:40 PM
$PHIO Phio Pharmaceuticals Corp. announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026. PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer. Thus far, a total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial. The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). No patients in the study have exhibited clinical progression of disease. To date, there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients.
0 · Reply
newsfile_corp
newsfile_corp Nov. 25 at 4:30 PM
https://nfne.ws/275716 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
0 · Reply
Latest News on PHIO
transition_state
transition_state Nov. 26 at 2:58 PM
0 · Reply
Treechain
Treechain Nov. 26 at 2:50 PM
$PHIO charts are starting to show buy
0 · Reply
Treechain
Treechain Nov. 26 at 2:28 PM
$PHIO phase 1b enrollment
0 · Reply
Erhnadgzl
Erhnadgzl Nov. 26 at 8:32 AM
$PHIO Preparations have begun for a very big deal that will happen soon.
0 · Reply
Erhnadgzl
Erhnadgzl Nov. 26 at 8:30 AM
$PHIO lets gooo 4 dolar guys
0 · Reply
ckruel
ckruel Nov. 25 at 9:33 PM
$PHIO On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial, which evaluates safety and tolerability, showed promising results with several patients achieving complete or partial responses, and no dose-limiting toxicities observed. This milestone advances PH-762 as a potential treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with pathology results expected in Q1 2026. Recent price target $14 usd
0 · Reply
KuruHabesha
KuruHabesha Nov. 25 at 6:03 PM
$PHIO Starter!
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Nov. 25 at 5:04 PM
$PHIO Seems weird to me - Old Bob buys stock and then makes announcement - wonder if his dream team did also or just friends and family - but even the pump was ineffective
0 · Reply
JimCramerisadoofus
JimCramerisadoofus Nov. 25 at 4:40 PM
$PHIO Phio Pharmaceuticals Corp. announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026. PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer. Thus far, a total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial. The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). No patients in the study have exhibited clinical progression of disease. To date, there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients.
0 · Reply
newsfile_corp
newsfile_corp Nov. 25 at 4:30 PM
https://nfne.ws/275716 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Nov. 25 at 3:26 AM
$PHIO If CEO buys does that mean there is no major announcements coming? Is a CEO have to follow black out rules when doing random transactions?
0 · Reply
LongAllDay
LongAllDay Nov. 24 at 9:34 PM
$PHIO CEO bought a used Hyundai worth of shares we are so blessed
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 24 at 8:00 PM
$PHIO CEO purchased 5,000 shares at $1.14 for a total of $5,700. Bitterman Robert J now owns 281,421 shares. https://ceo-buys.com
0 · Reply
PitaPierogi
PitaPierogi Nov. 24 at 1:45 PM
$PHIO STRONG BUY. 14. LETS GOOOO $SPY $QQQ $SMCI $NVDA
0 · Reply
trader_23
trader_23 Nov. 24 at 12:07 AM
0 · Reply
PitaPierogi
PitaPierogi Nov. 22 at 12:02 AM
0 · Reply
DosGatos
DosGatos Nov. 21 at 8:51 PM
$PHIO Santa Geeeeeert is coming he has a bunch of new shares and a reverse split for all the good shareholders!!
1 · Reply
JimCramerisadoofus
JimCramerisadoofus Nov. 21 at 4:51 PM
0 · Reply
PitaPierogi
PitaPierogi Nov. 21 at 3:21 PM
$PHIO This S-3 is NOT dilution. It’s only a registration so warrant holders can sell later. No new shares hit the market today. • Warrants have a strike price of $2.05. At today’s price ($1.19), no one will exercise — they’d lose money. • If warrants aren’t exercised, shares do NOT exist. They are not in the float, not in the market, not diluting anything. • Current float is only ~10.3M shares. PHIO is still a tiny float micro-cap, nothing changed there. • Selling CANNOT happen until: SEC declares the S-3 “effective” Stock trades above $2.05 Holders choose to exercise THEN they can sell We are 0/4 on those conditions → NO selling pressure from warrants right now. • PHIO would get $24M in cash —but ONLY if price goes above $2.05 and warrants get exercised. Right now: $0 raised, no dilution. • CEO just increased his stake to 275,000 shares. Insider buying ≠ dilution. That’s confidence.
0 · Reply
PitaPierogi
PitaPierogi Nov. 21 at 3:20 PM
$PHIO This S-3 is NOT dilution. It’s only a registration so warrant holders can sell later. No new shares hit the market today. • Warrants have a strike price of $2.05. At today’s price ($1.19), no one will exercise — they’d lose money. • If warrants aren’t exercised, shares do NOT exist. They are not in the float, not in the market, not diluting anything. • Current float is only ~10.3M shares. PHIO is still a tiny float micro-cap, nothing changed there. • Selling CANNOT happen until: SEC declares the S-3 “effective” Stock trades above $2.05 Holders choose to exercise THEN they can sell We are 0/4 on those conditions → NO selling pressure from warrants right now. • PHIO would get $24M in cash —but ONLY if price goes above $2.05 and warrants get exercised. Right now: $0 raised, no dilution. • CEO just increased his stake to 275,000 shares. Insider buying ≠ dilution. That’s confidence.
0 · Reply
Treechain
Treechain Nov. 21 at 1:57 PM
$PHIO ????? wtf so selling stock holders 11.8 mil shares are being offered for sale by the company? what does that mean?
1 · Reply
Bigmoney47
Bigmoney47 Nov. 21 at 10:20 AM
$PHIO 9%📈 pre-market, What's wrong with the company? Will it close soon .
0 · Reply